Head-to-head · WeighScore
Lttl vs Ravia Health
The verdict
Lttl takes it — 66.1/100 to 59.2/100.
Lttl grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Lttl (pronounced 'little') is a direct-to-consumer telehealth brand offering compounded semaglutide and tirzepatide, a low-dose 'microdose' line, and longevity peptides.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Lttl | Ravia Health |
|---|---|---|
| WeighScore | 66.1/100 | 59.2/100 |
| Grade | C | C |
| Scorecard rank | #205 | #347 |
| Semaglutide | $199/mo (all doses, compounded) | Not disclosed |
| Tirzepatide | $279/mo (all doses, compounded) | Not disclosed |
| Coverage | Coverage not published | 1 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Injection only |
Graded #205 · C
Strengths
- Publishes the full price matrix — every medication, form and commitment length — on a public /plans page before checkout
- Flat dose pricing: 'Same price at every dose,' so moving to a higher dose does not raise the monthly bill
- States plainly that its compounded GLP-1s 'are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality'
- Microdose line prices low-dose semaglutide or tirzepatide at $149/mo month-to-month for people sensitive to side effects
- Oral ODT semaglutide offered for members who want to avoid injections
Where it loses points
- Partner pharmacies are never named — the site refers only to 'a partner U.S. pharmacy' (a material disclosure gap for a YMYL purchase)
- The advertised 'Plans start at $129/mo' is the 12-month prepay rate; true month-to-month is $199 semaglutide and $279 tirzepatide
- No public list of states served — eligibility depends on where unnamed 'partner providers are licensed'
- Site banner promises 'Prescribed and shipped within 48 hours' while the shipping policy states 2-5 business days to process plus 3-7 to deliver
- Medications cannot be returned or refunded once they ship from the pharmacy
Graded #347 · C
Strengths
- Integrative psychiatry model combines GLP-1 weight-loss with mental health and metabolic care under one board-certified NP provider
- Founded by Dr. Raashida Portier (DNP, PMHNP-BC, FNP-BC); named clinician with dual board certifications in psychiatry and family medicine
- Membership-supported ongoing care from $49/month provides medication management structure with consistent follow-up
- Labs and metabolic workup available as part of integrative psychiatry model; lab testing noted in weight-loss program
- Weight-loss page claims nationwide availability via Lyv Health partnership for eligible patients
Where it loses points
- GLP-1 medication pricing fully gated — not disclosed until consultation; compounded vs. brand status unclear on public pages
- Primarily a psychiatric practice — weight loss is a secondary service, not the core offering or brand identity
- Core services explicitly Florida-only; nationwide weight-loss claim relies on Lyv Health partnership with unverified state coverage
- No LegitScript certification or third-party accreditation found on public pages
- Small single-provider practice with no published outcomes data or external reviews available
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.